All News

Patients, Consumers, and Caregivers Are Increasingly Interested in Self-Determination and Convenience.

V116 (Capvaxive; Merck) elicited higher immune responses than the comparator for the serotypes that are unique to the vaccine, according to studies submitted to the FDA.

Pharmacists can also counsel on prevention measures and self-management for fungal infections

Secondhand exposure to e-cigarette smoke may increase risk of pediatric atopic dermatitis in children.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Durvalumab plus carboplatin and paclitaxel, continued with durvalumab monotherapy, decreased the risk of disease progression or death by 58%.

Mim8 had a safe and well-tolerated profile, with no deaths or thrombotic events reported for patients with hemophilia A.

With this approval, Yimmugo is the first approved product from the Biotest Next Level production facility.

Since 1997, Pharmacy Times has compiled these results to collect the most up-to-date information about which brands pharmacists recommend most often to patients.

Data show that among individuals 60 years and older, the estimated rate of Guillain-Barré syndrome (GBS) after receiving an RSV vaccine was 5.0 and 1.5 per million doses of Abrysvo and Arexvy, respectively.

Persistent chemotherapy drug shortages challenge oncology providers. American Oncology Network employs a drug shortage committee for organized shortage management that involves pharmacists and interdisciplinary stakeholders.

As patients take more proactive roles in their health, they may feel too intimidated to discuss herbal medicinal use with their providers or may be unaware of potential interactions with their drug therapies.

The study results also found that exposure to tree canopy area may protect children from asthma development; however, efficacy decreased as weed pollen exposure increased.

Zanubrutinib shows potential in treating patients with treatment-naïve high-risk chronic lymphocytic leukemia and/or small lymphocytic lymphoma with del(17p) and/or TP53 mutation.

Precision medicine takes a proactive stance by leveraging genetic insights to guide treatment decisions from the outset.

OTC products are cost-effective and offer patients a convenient self-treatment option.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Brentuximab vedotin in combination with lenalidomide and rituximab had a favorable safety profile for patients with relapsed/refractory diffuse large B-cell lymphoma.

The new findings were presented as an oral presentation at the 2024 European Calcified Tissue Society Congress, held from May 25, 2024, to May 28, 2024.

Researchers are working to solve consistency and ecological and ethical concerns in pharmaceutical formulations

Repotrectinib has also shown significant efficacy in ROS1 fusion-positive non¬–small cell lung cancer (NSCLC), which was also studied in the TRIDENT-1 trial.

This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.